BR112018010635A2 - linhagens celulares estáveis para a produção retroviral - Google Patents

linhagens celulares estáveis para a produção retroviral

Info

Publication number
BR112018010635A2
BR112018010635A2 BR112018010635A BR112018010635A BR112018010635A2 BR 112018010635 A2 BR112018010635 A2 BR 112018010635A2 BR 112018010635 A BR112018010635 A BR 112018010635A BR 112018010635 A BR112018010635 A BR 112018010635A BR 112018010635 A2 BR112018010635 A2 BR 112018010635A2
Authority
BR
Brazil
Prior art keywords
nucleic acid
retroviral
cell lines
relates
acid sequences
Prior art date
Application number
BR112018010635A
Other languages
English (en)
Portuguese (pt)
Inventor
Pallant Celeste
Vink Conrad
Vamva Eirini
Johnson Sabine
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1520761.6A external-priority patent/GB201520761D0/en
Priority claimed from GBGB1609303.1A external-priority patent/GB201609303D0/en
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112018010635A2 publication Critical patent/BR112018010635A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C12N15/8673—Special methods for packaging systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/00051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Seal Device For Vehicle (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018010635A 2015-11-24 2016-11-21 linhagens celulares estáveis para a produção retroviral BR112018010635A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1520761.6A GB201520761D0 (en) 2015-11-24 2015-11-24 Stable cell lines for retroviral production
GBGB1609303.1A GB201609303D0 (en) 2016-05-26 2016-05-26 Stable cell lines for retroviral production
PCT/EP2016/078336 WO2017089308A1 (en) 2015-11-24 2016-11-21 Stable cell lines for retroviral production

Publications (1)

Publication Number Publication Date
BR112018010635A2 true BR112018010635A2 (pt) 2018-11-27

Family

ID=57354376

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010635A BR112018010635A2 (pt) 2015-11-24 2016-11-21 linhagens celulares estáveis para a produção retroviral

Country Status (17)

Country Link
US (3) US20170145388A1 (https=)
EP (2) EP3489353B8 (https=)
JP (1) JP7098521B2 (https=)
KR (1) KR102091957B1 (https=)
CN (1) CN108291208A (https=)
AU (1) AU2016360763B2 (https=)
BR (1) BR112018010635A2 (https=)
CA (1) CA3006288A1 (https=)
DE (1) DE102016122316A1 (https=)
ES (2) ES2939617T3 (https=)
FR (1) FR3044016A1 (https=)
GB (1) GB2544892B (https=)
IL (2) IL259254A (https=)
IT (1) IT201600117326A1 (https=)
RU (1) RU2752498C2 (https=)
SA (1) SA518391623B1 (https=)
WO (1) WO2017089308A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1970681A4 (en) * 2005-12-21 2011-01-19 Ishida Seisakusho ROTARY MEASURING DEVICE
EP3380605A1 (en) 2015-11-24 2018-10-03 GlaxoSmithKline Intellectual Property Development Limited Transient transfection method for retroviral production
GB201706121D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
GB201715052D0 (en) 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
EP3696272A1 (en) 2017-12-22 2020-08-19 Oxford BioMedica (UK) Limited Retroviral vector
KR20210108406A (ko) * 2018-12-21 2021-09-02 론자 워커스빌 아이엔씨. 바이러스 벡터의 자동화된 생산
WO2021041322A1 (en) * 2019-08-23 2021-03-04 Lonza Walkersville, Inc. Methods and constructs for production of lentiviral vector
US12398404B2 (en) 2019-12-18 2025-08-26 Lonza Walkersville, Inc. Methods and constructs for transient production of lentiviral vector
GB202004371D0 (en) 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
GB202005096D0 (en) 2020-04-07 2020-05-20 Glaxosmithkline Modified vectors for production of retrovirus
CN113528515B (zh) * 2020-04-22 2023-05-05 中国科学院分子植物科学卓越创新中心 基于CRISPR-Cas13a干预阻断病毒逆转录转座的技术
EP4150097A1 (en) * 2020-05-15 2023-03-22 Ivexsol, Inc. Compositions and methods for producing stable viral vector producer cells for cell and gene therapy
CN112430582B (zh) * 2020-12-04 2022-05-03 北京艺妙神州医药科技有限公司 一种慢病毒稳定包装细胞系及其制备方法
CN118638226A (zh) 2021-03-19 2024-09-13 葛兰素史密斯克莱知识产权发展有限公司 靶向密蛋白3的嵌合抗原受体和治疗癌症的方法
US20240200100A1 (en) * 2021-04-20 2024-06-20 The Regents Of The University Of California Packaging cells with targeted gene knockouts that improve retroviral vector titers
WO2024149284A1 (en) * 2023-01-10 2024-07-18 Nanjing Legend Biotech Co., Ltd. Regulatory sequences and uses thereof
WO2024218341A1 (en) 2023-04-19 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for car-t and car-nk cells
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
CN116804211A (zh) * 2023-05-09 2023-09-26 浙江大学 促进猪病毒复制的malt1稳转细胞系及其构建方法
WO2026032970A1 (en) 2024-08-07 2026-02-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Cd4-specific chimeric antigen receptor and methods and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
ATE309000T1 (de) * 1995-06-27 2005-11-15 Bavarian Nordic As Verkapselte zellen die virenpartikeln produzieren
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
WO2000065077A1 (en) * 1999-04-22 2000-11-02 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
US6677155B1 (en) * 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
EP1173597A1 (en) * 1999-04-29 2002-01-23 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
US20060057553A1 (en) * 2000-05-30 2006-03-16 Estuardo Aguilar-Cordova Chimeric viral vectors for gene therapy
US6689601B2 (en) * 2000-09-01 2004-02-10 E. I. Du Pont De Nemours And Company High growth methanotropic bacterial strain
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE10111433A1 (de) * 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
HUP0402659A3 (en) 2001-05-30 2008-07-28 Glaxo Group Ltd Chromosome-based platforms
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
SI1504108T1 (sl) * 2002-02-01 2013-07-31 Oxford Biomedica (Uk) Limited Lentiviralni vektor
CA2501168A1 (en) * 2002-11-25 2004-06-10 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ati promoters
NZ550411A (en) * 2004-04-28 2009-08-28 Univ Pennsylvania Polyvalent viral vectors and a system for production thereof
EP1652932A1 (en) * 2004-11-02 2006-05-03 GBF Gesellschaft für Biotechnologische Forschung mbH Method for the generation of virus producing cell lines and cell lines
WO2006057289A1 (ja) * 2004-11-24 2006-06-01 Anaeropharma Science Inc. 新規シャトルベクター
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
WO2010131747A1 (ja) * 2009-05-15 2010-11-18 国立大学法人 東京大学 ウイルス産生細胞
SI2480678T1 (sl) * 2010-09-02 2014-06-30 Molmed Spa Stabilno proizvajanje lentivirusnih vektorjev
US9273324B2 (en) * 2010-12-05 2016-03-01 Andrew S. Belmont Recombinant gene expression
WO2012170431A2 (en) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
FR2979919B1 (fr) * 2011-09-12 2015-12-11 Centre Nat Rech Scient Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1
GB201202516D0 (en) * 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
JP2015529466A (ja) 2012-09-14 2015-10-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター
ES2786051T3 (es) * 2012-10-25 2020-10-08 Tocagen Inc Vector retroviral con casete de mini-promotor
WO2015031686A1 (en) * 2013-08-30 2015-03-05 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
GB2538324A (en) * 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Packaging cell line for retroviral production
GB2538321A (en) * 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Artificial chromosome for retroviral production
EP3351851B1 (en) * 2015-09-01 2019-10-09 Signify Holding B.V. Lighting device with a wireless communication antenna
EP3380605A1 (en) * 2015-11-24 2018-10-03 GlaxoSmithKline Intellectual Property Development Limited Transient transfection method for retroviral production

Also Published As

Publication number Publication date
RU2018122636A (ru) 2019-12-25
US20200123505A1 (en) 2020-04-23
DE102016122316A1 (de) 2017-05-24
EP3489353B1 (en) 2023-07-26
JP2018534937A (ja) 2018-11-29
AU2016360763A1 (en) 2018-05-31
EP3380604A1 (en) 2018-10-03
RU2752498C2 (ru) 2021-07-28
EP3489353A1 (en) 2019-05-29
IL282603A (en) 2021-06-30
US20180320147A1 (en) 2018-11-08
EP3489353B8 (en) 2023-08-30
EP3489353C0 (en) 2023-07-26
IL259254A (en) 2018-07-31
EP3380604B1 (en) 2022-12-28
US20170145388A1 (en) 2017-05-25
WO2017089308A1 (en) 2017-06-01
JP7098521B2 (ja) 2022-07-11
ES2959326T3 (es) 2024-02-23
RU2018122636A3 (https=) 2020-04-02
IT201600117326A1 (it) 2018-05-21
GB2544892B (en) 2017-11-15
IL282603B (en) 2022-05-01
GB201619643D0 (en) 2017-01-04
KR20180079351A (ko) 2018-07-10
CN108291208A (zh) 2018-07-17
AU2016360763B2 (en) 2020-11-05
KR102091957B1 (ko) 2020-03-20
FR3044016A1 (fr) 2017-05-26
SA518391623B1 (ar) 2022-10-30
CA3006288A1 (en) 2017-06-01
GB2544892A (en) 2017-05-31
ES2939617T3 (es) 2023-04-25

Similar Documents

Publication Publication Date Title
BR112018010635A2 (pt) linhagens celulares estáveis para a produção retroviral
BR112018010639A2 (pt) método de transfecção transitória para produção retroviral.
CL2021002739A1 (es) Proteína crispr de prevotella y francisella 1 (cpf1) aislada de acidaminococcus sp. bv3l6; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
EP4527459A3 (en) Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
WO2020198509A3 (en) Modified oligonucleotides with increased stability
CA3139195A1 (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
MX2017016688A (es) Nuevas enzimas y sistemas crispr.
CO2019006485A2 (es) Anticuerpos y metodos de su utilizacion
EA202191313A1 (ru) Композиции на основе липидных наночастиц
WO2020086144A3 (en) APPLICATIONS OF CRISPRi IN HIGH THROUGHPUT METABOLIC ENGINEERING
WO2019173692A3 (en) Anti-cd73 antibodies and methods of use thereof
WO2016160844A3 (en) Methods and compositions for combinatorial barcoding
MX390848B (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
BRPI0714495B8 (pt) lentivírus deficiente para replicação recombinante pseudotipado
EP4431607A3 (en) High-throughput precision genome editing
MX372651B (es) ARN SINTÉTICO PARA SU Uso EN EL TRATAMIENTO DE LA EPIDERMÓLISIS AMPOLLOSA DISTRÓFICA.
BR112017016681A2 (pt) vetor de coexpressão de vacina e moléculas coestimulatórias
CR20200192A (es) Métodos y composiciones para la producción de nucleósido trifosfatos y ácidos ribonucleicos
CY1114483T1 (el) Νεα ρυθμιστικα στοιχεια
MX2019007248A (es) Enzimas de polimerizacion para reacciones de secuenciacion.
UA118014C2 (uk) Спосіб модифікації днк-мішені
WO2015051199A3 (en) Modified pseudomonas exotoxin a
WO2015042308A3 (en) Rna-based hiv inhibitors
BR112017013597A2 (pt) molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.